This CPB is revised to state that RiaSTAP (human fibrinogen concentrate) is considered medically necessary for the treatment of acute bleeding episodes in persons with congenital fibrinogen deficiency when the diagnosis of congenital fibrinogen deficiency has been confirmed by blood coagulation testing. (The previous version of the CPB limited RiaSTAP use to persons with a poor response to cryoprecipitate in previous bleeding episodes.)